Evaluating plaque regression in young patients with familial hypercholesterolemia through aggressive lipid lowering therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the potential for significant plaque regression in young adults diagnosed with heterozygous familial hypercholesterolemia, specifically those aged 18 to 50 years. Participants will undergo early and intensive lipid lowering therapy to assess its effectiveness in reversing coronary artery disease progression. The study aims to determine if aggressive treatment can lead to improved cardiovascular outcomes in this high-risk population. The research will focus on measuring changes in plaque characteristics over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with heterozygous familial hypercholesterolemia
* Adult between 18 and 50 years old
* LDL cholesterol levels above 100 mg/dl (\>2.6 mmol/L) at inclusion

Exclusion Criteria:

* Renal insufficiency, defined as eGFR \< 30 ml/min
* History of atherosclerotic cardiovascular events
* Atrial fibrillation
* Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
* Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.

Where it's running

• Amsterdam UMC, location AMC
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Erik SG Stroes, MD, PhD — Amsterdam UMC, location AMC
• Study coordinator: Erik SG Stroes, MD, PhD
• Email: e.s.stroes@amsterdamumc.nl
• Phone: +205669111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if early heart plaque can be reduced with statin and colchicine in people at risk

  This trial tests whether high‑intensity statin and low‑dose colchicine, taken alone or together, can reduce heart plaque in people at risk for heart disease.

  Recruiting at 17 sites Phase 3 Duke University · Birmingham, Alabama and 22 other locations · NCT07232069

• Clinical features, treatments, and outcomes in inflammation-associated non-rapidly-progressive coronary artery disease

  This study will see how current treatments, inflammation markers, and patient characteristics relate to outcomes in people with inflammation-associated non-rapidly-progressive coronary artery disease (INR-CAD).

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06845410

• Exploring coronary artery disease progression using radial wall strain

  This study is testing if a new way to measure heart artery strain can help predict how quickly heart disease gets worse in people who recently had a heart attack.

  Recruiting China National Center for Cardiovascular Diseases · Beijing · NCT06040073

• Investigating characteristics of a special type of coronary artery disease

  This study is trying to understand the unique features of a fast-progressing type of coronary artery disease by comparing patients with this condition to those with a more common form of the disease.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06007248

• Evaluating comprehensive treatment for rapidly-progressive coronary artery disease

  This study is testing a new treatment plan for people with rapidly-progressive coronary artery disease that includes medication and procedures to see if it helps them feel better and manage their condition.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT05860400

• Evaluating heart patients with previous bypass surgery for graft issues and heart disease progression

  This study is trying to see how heart patients who had bypass surgery and are having chest pain again are doing over time, especially looking at issues with their grafts and heart disease.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam · NCT04772768

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.